The stakes are considerable. Chronic neuroinflammation is now strongly implicated in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and traumatic brain injury. In Alzheimer’s, amyloid-beta plaques and tau tangles activate microglia and astrocytes, and the resulting inflammatory mediators in turn accelerate amyloid deposition and synaptic dysfunction—a self-reinforcing loop. In Parkinson’s, pro-inflammatory cytokines and reactive oxygen species released by activated microglia promote the death of dopaminergic neurons in the substantia nigra. In multiple sclerosis, peripheral immune cells infiltrate the central nervous system and strip away myelin, while in traumatic brain injury an acute inflammatory surge gives way to chronic secondary inflammation that compounds long-term neurological impairment. The review’s authors emphasize that neuroinflammation is not merely a downstream consequence of these diseases but an active driver of their progression.

At the molecular level, several signaling cascades orchestrate the inflammatory response. The NF-κB pathway, activated when pattern-recognition receptors such as Toll-like receptors detect pathogen- or damage-associated molecular patterns, controls the transcription of pro-inflammatory genes, cytokines, adhesion molecules, and inducible nitric oxide synthase. The NLRP3 inflammasome, a multiprotein complex central to innate immunity, activates caspase-1 and promotes maturation of the potent inflammatory cytokines IL-1β and IL-18. The MAPK pathway—spanning the ERK, JNK, and p38 kinases—regulates inflammatory gene expression and cellular stress responses, while oxidative stress and mitochondrial damage amplify the entire signaling network. Even epigenetic modifications such as histone acetylation and DNA methylation tune the activation state of microglia and astrocytes, adding another layer of regulatory complexity that any diagnostic platform must ultimately contend with.

The cellular choreography is equally intricate. Resting microglia constantly patrol the neural microenvironment, but upon activation they polarize toward broadly pro-inflammatory M1 or anti-inflammatory M2 phenotypes. M1 microglia secrete TNF-α, IL-1β, and IL-6, which can be neurotoxic, while M2 microglia promote tissue regeneration. Astrocytes, the most abundant glial cells in the brain, similarly divide into neurotoxic A1 and neuroprotective A2 reactive states. Critically, the two cell types communicate: activated microglia release IL-1α, TNF-α, and the complement component C1q, which push astrocytes toward the A1 state, creating a vicious cycle of sustained inflammation. Both cell types also govern blood-brain barrier integrity and immune cell trafficking into the brain, making them central to neuroimmune balance—and attractive targets for biomarker-based monitoring.

The biomarker landscape reflects this complexity. Cytokines such as IL-1β, IL-6, TNF-α, and interferon-gamma rise in multiple neurodegenerative conditions and correlate with disease severity. Chemokines including CCL2, CXCL8, and CXCL10 recruit immune cells and mediate communication between the central nervous system and the periphery. MicroRNAs—particularly miR-155, miR-146a, and miR-124—regulate inflammatory pathways post-transcriptionally and remain stable in biological fluids, making them strong candidates for non-invasive diagnostics. Protein markers such as glial fibrillary acidic protein (GFAP), Iba1, and S100B signal glial activation and neuronal injury, while exosomal biomarkers loaded with inflammatory molecules offer a minimally invasive window into the brain. The problem, the review notes, is that conventional diagnostics cannot reliably capture these signals early enough.

That is where DNA nanotechnology enters the picture. Because DNA strands self-assemble through predictable Watson-Crick base pairing, researchers can program nanostructures of virtually any shape and function—from simple duplexes and hairpins to DNA tiles, nanotubes, and three-dimensional origami architectures folded from a long scaffold strand and short staple strands. These structures can be decorated with fluorophores, enzymes, or nanoparticles to amplify signals, and they can be engineered to respond dynamically to molecular interactions, enabling real-time analyte monitoring. DNA aptamers—short single-stranded oligonucleotides selected through the SELEX process—bind targets ranging from proteins to whole cells with high affinity, and offer practical advantages over antibodies: they are easy to synthesize, chemically stable, and minimally immunogenic.

The analytical performance figures reported in the review are striking. A DNA four-way-junction biosensor detected TNF-α down to 0.07 picograms per milliliter in buffer and 0.14 picograms per milliliter in ten percent diluted human serum. An aptamer-MXene hybrid electrochemical biosensor simultaneously measured TNF-α and interferon-gamma in diluted serum with detection limits of 0.15 and 0.12 picograms per milliliter respectively, delivering results in ten minutes or less. An IL-6 electrochemical immunosensor achieved limits of 2.34 picograms per milliliter in human cerebrospinal fluid and 11.83 picograms per milliliter in serum, with response times of roughly three minutes and clear point-of-care potential. A label-free IL-6 aptasensor reached 2.9 picograms per milliliter in human serum. Electrochemical platforms built on graphene and gold nanoparticles, fluorescent FRET-based systems, and CRISPR-Cas12 and Cas13 detection platforms each bring complementary strengths in sensitivity, multiplexing, and portability.

Artificial intelligence is the second half of the equation. Machine learning models—including support vector machines, random forests, artificial neural networks, and convolutional neural networks—can extract meaningful patterns from the large, noisy datasets that biosensors generate, distinguishing true biomarker signals from background noise and deconvoluting overlapping signals in multiplexed assays. AI can also accelerate sensor design itself: optimization algorithms and generative models can predict how changes in material composition, geometry, and functionalization will affect performance, replacing laborious trial-and-error prototyping. Predictive models built on temporal biomarker data could forecast disease onset or progression, while intelligent data fusion might integrate biosensor outputs with clinical, imaging, and multi-omics information. The review is careful, however, to note that many of these AI capabilities rest on transferable or indirect evidence, and that fully integrated AI-driven DNA nanobiosensor systems validated on neuroinflammatory markers in clinical samples remain scarce.

The translational hurdles are substantial. DNA nanostructures demand precise, costly nanofabrication, and even minor inconsistencies in immobilizing recognition elements on sensor surfaces can swing sensitivity dramatically. Nuclease degradation, nonspecific interactions, and matrix effects in complex biological samples can erode the signal reliability demonstrated under laboratory conditions. On the computational side, AI models require large, high-quality, diverse training datasets that biosensor research rarely provides, raising risks of overfitting, algorithmic bias, and the black-box opacity that makes clinicians wary. Biocompatibility looms equally large for in vivo applications, since nanomaterials may trigger cytotoxicity, immune reactions, or long-term tissue deposition, and the long-term consequences of nanomaterial exposure remain poorly characterized. Regulatory frameworks for nanotechnology-based medical devices are still fragmented, and biosensors that collect sensitive genetic and biological data raise thorny privacy and consent questions.

Looking forward, the review sketches a vision of next-generation smart platforms combining DNA nanostructures with graphene, quantum dots, and metallic nanoparticles, integrated with microfluidics, wearable or implantable formats, and even self-powered designs that harvest bioenergy. In the longer term, the authors envision theranostic systems in which DNA nanostructures detect disease-specific biomarkers and release therapeutic payloads—drugs, genes, or siRNA—in response to stimuli such as pH shifts, enzyme activity, or oxidative stress, with AI guiding personalized treatment decisions. But they are emphatic that such closed-loop, AI-guided theranostics remain conceptual: no clinical system has yet demonstrated efficacy or long-term safety in patients with neuroinflammatory disorders. The path to the clinic, they conclude, runs through standardized fabrication protocols, multicenter validation in diverse patient populations, scalable manufacturing, explainable AI, and rigorous regulatory compliance. If those obstacles can be cleared, programmable DNA and machine intelligence may finally give clinicians the early-warning system that neuroinflammation has, until now, denied them.

Subject of Research: AI-integrated DNA nanobiosensors for detecting neuroinflammatory biomarkers

Article Title: AI-integrated DNA nanobiosensors for neuroinflammation: biomarker detection, intelligent analysis, and translational perspectives

Article References: Porwal, M., Malviya, R., Chandra, P., Sridhar, S. B., Shareef, J., Wadhwa, T., & Balusamy, B. (2026). AI-integrated DNA nanobiosensors for neuroinflammation: biomarker detection, intelligent analysis, and translational perspectives. Results in Chemistry, 31, Article 103919. https://doi.org/10.1016/j.rechem.2026.103919

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.103919

Keywords: neuroinflammation, DNA nanobiosensors, artificial intelligence, biomarkers, cytokines, microglia, astrocytes, aptamers, DNA origami, electrochemical biosensors, CRISPR, neurodegenerative disease